Rapport Therapeutics Future Growth
Future criteria checks 0/6
Rapport Therapeutics's earnings are forecast to decline at 32% per annum. EPS is expected to grow by 23.5% per annum.
Key information
-32.0%
Earnings growth rate
23.5%
EPS growth rate
| Pharmaceuticals earnings growth | 22.9% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 09 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -157 | -148 | -133 | 3 |
| 12/31/2025 | N/A | -117 | -110 | -103 | 3 |
| 12/31/2024 | N/A | -83 | -73 | -68 | 3 |
| 6/30/2024 | N/A | -63 | -53 | -50 | N/A |
| 3/31/2024 | N/A | -51 | -43 | -40 | N/A |
| 12/31/2023 | N/A | -35 | -29 | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAPP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RAPP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RAPP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if RAPP's revenue is forecast to grow faster than the US market.
High Growth Revenue: RAPP is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RAPP's Return on Equity is forecast to be high in 3 years time